These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Interferon in the therapy of hemoblastoses (a review)]. Iavorkovskiĭ LI; Iavorkovskiĭ LL Ter Arkh; 1989; 61(10):33-9. PubMed ID: 2481891 [No Abstract] [Full Text] [Related]
4. [Chronic myeloproliferative neoplasms]. Griesshammer M; Döhner K Dtsch Med Wochenschr; 2014 Feb; 139(6):243-6. PubMed ID: 24473840 [No Abstract] [Full Text] [Related]
5. Focus on myeloproliferative diseases and myelodysplastic syndromes. Van Etten RA; Shannon KM Cancer Cell; 2004 Dec; 6(6):547-52. PubMed ID: 15607959 [No Abstract] [Full Text] [Related]
7. The selection of patients for splenectomy. Weatherall DJ Ann R Coll Surg Engl; 1971 Jan; 48(1):29. PubMed ID: 5572221 [No Abstract] [Full Text] [Related]
8. The myelodysplastic syndromes and myeloproliferative disorders. Williams JL Clin Lab Sci; 2004; 17(4):223-34. PubMed ID: 15559729 [TBL] [Abstract][Full Text] [Related]
9. [Splenectomy in malignant hematological diseases]. Steruská M; Hrubisko M; Lipsic T; Schnorrer M; Cárský S Vnitr Lek; 1980 Oct; 26(10):951-7. PubMed ID: 7467147 [No Abstract] [Full Text] [Related]
10. Recent advances in biological and therapeutic aspects of myeloproliferative disorders. Mancini M; Diverio D; Alimena G; Mandelli F Curr Opin Hematol; 1994 Jul; 1(4):261-7. PubMed ID: 9371292 [TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative disorder therapy: assessment and management of adverse events--a psychiatrist's perspective. McDonald G Hematol Oncol; 2009 Jun; 27 Suppl 1():14-6. PubMed ID: 19468981 [TBL] [Abstract][Full Text] [Related]
12. The management of elderly patients with myeloproliferative disorders. Tura S Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340 [No Abstract] [Full Text] [Related]
13. New perspectives in managing myeloproliferative disorders: focus on the patient. Birgegård G Hematol Oncol; 2009 Jun; 27 Suppl 1():5-7. PubMed ID: 19468983 [TBL] [Abstract][Full Text] [Related]
14. [Recommendations for the cytogenetic management of myeloproliferative syndromes proposed by the French Group for Cytogenetic Hematology]. Groupe Français de Cytogénétique Hématologique (GFCH) Pathol Biol (Paris); 2004 Jun; 52(5):241-4. PubMed ID: 15217703 [No Abstract] [Full Text] [Related]
16. Myeloproliferative disorder therapy: assessment and management of adverse events--a cardiologist's perspective. Kenny D Hematol Oncol; 2009 Jun; 27 Suppl 1():8-10. PubMed ID: 19468985 [TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative disorders: III. CML: Further studies on the role of cytogenetics in diagnosis, prognosis and management. Fuscaldo KE; Brodsky I; Kahn SB; Conroy JF; Marfurt K Haematologica; 1981 Aug; 66(4):461-88. PubMed ID: 6797881 [No Abstract] [Full Text] [Related]
18. [How extensive are the present indications for bone marrow transplantation?]. Gmür J Schweiz Med Wochenschr; 1985 May; 115(21):738-43. PubMed ID: 3892662 [TBL] [Abstract][Full Text] [Related]
19. [Metamorphosis of chronic myeloproliferative diseases]. Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716 [No Abstract] [Full Text] [Related]
20. [Experiences with the treatment of acute leukemias and blast crises in chronic myeloproliferative diseases]. Eggeling T; Braumann D; Mainzer K Med Welt; 1981 Jul; 32(27):1077-80. PubMed ID: 6943405 [No Abstract] [Full Text] [Related] [Next] [New Search]